Show
Sort by
-
Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
The unified airway hypothesis : evidence from specific intervention with anti–IL-5 biologic therapy
-
- Journal Article
- A1
- open access
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials
-
- Journal Article
- A1
- open access
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps
-
Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB144-AB144 -
- Journal Article
- A1
- open access
Dupilumab improves health related quality of life : results from the phase 3 SINUS studies
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
-
Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis Reply
-
Role of biologics in chronic rhinosinusitis with nasal polyposis : state of the art review
-
ARIA digital anamorphosis : digital transformation of health and care in airway diseases from research to practice
-
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
-
Cabbage and fermented vegetables : from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19
-
- Journal Article
- A1
- open access
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
-
International consensus statement on allergy and rhinology : rhinosinusitis 2021
-
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials